943320-48-7

Basic information

• Product Name: 3-(1H-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
• Synonyms: 3-(1H-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
• CAS NO: 943320-48-7
• Molecular Weight: 227.189
• Mol File: 943320-48-7.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-(1H-imidazol-1-yl)-5-(trifluoromethyl)benzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1H-imidazol-1-yl)-5-(trifluoromethyl)benzenamine(943320-48-7)
• EPA Substance Registry System: 3-(1H-imidazol-1-yl)-5-(trifluoromethyl)benzenamine(943320-48-7)

Safety Data

• Hazardous Substances Data: 943320-48-7(Hazardous Substances Data)

Usage

Uses

3-(1H-Imidazol-1-yl)-5-(trifluoromethyl)-aniline is a reactant used in the synthesis of novel Bcr/Abl inhibitors as anti-cancer drugs. Nilotinib (N465300) impurity, which might be useful in treatment of chronic myelogenous leukemia.

Upstream product

• 288-32-4 1H-imidazole 
• 54962-75-3 [3-bromo-5-(trifluoromethyl)phenyl]amine 

Downstream Products

• 1234798-39-0 N-(5-(1H-imidazol-1-yl)-3-(trifluoromethyl)-phenyl)-4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-benzamide 

Relevant articles and documents

Nilotinib hydrochloride bulk drug impurity and preparation method thereof

The invention provides a preparation method of a nilotinib hydrochloride bulk drug impurity. The preparation method comprises the following steps: S1) reducing a compound as shown in a formula (II) to obtain a compound as shown in a formula (III); and S2) subjecting the compound as shown in the formula (III) to reacting with imidazole to obtain the nilotinib hydrochloride bulk drug impurity as shown in the formula (I). The formulas are as defined in the specification, and X in the formulas is halogen. Compared with the prior art, the preparation method of the impurity in the initial raw material of nilotinib hydrochloride provided by the invention has the advantages that raw materials are easy to obtain, a process route is relatively short, precious metals such as palladium can be prevented from being used for a reaction, quinoline compounds are not used, and residues of the quinoline compounds are avoided; and the method can be used for process development, production, quality standard establishment and quality control links of nilotinib, and provides technical support for the medication safety of the monohydrate nilotinib hydrochloride.

METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES

The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.

Hybrid compounds as new Bcr/Abl inhibitors

A series of 2,4-disubstituted thiazole derivatives were designed and synthesized as new Bcr/Abl inhibitors by hybriding the structural moieties from FDA approved imatinib, nilotinib and dasatinib. The new inhibitors strongly suppressed the activity of Bcr/Abl kinase and potently inhibited the proliferation of K562 and KU812 leukemia cancer cells. Compound 4i displayed comparable potency with that of nilotinib in both biochemical kinase assay and cancer cell growth inhibition assay. These inhibitors might serve as lead compounds for further developing new anticancer drugs.